Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-31
2011-05-31
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235500, C514S331000, C544S126000, C546S186000, C546S207000, C546S234000, C546S247000
Reexamination Certificate
active
07951821
ABSTRACT:
This invention discloses and claims a compound of general formula (I)in which R1represents either a hydrogen atom, or an optionally substituted alkyl group, or a cycloalkylalkyl group, or an optionally substituted phenylalkyl group, or an alkenyl group, X represents a hydrogen atom or one or more substituents chosen from halogen atoms and trifluoromethyl, alkyl and alkoxy groups, R2represents one or more substituents chosen from halogen atoms, optionally substituted alkoxy and optionally substituted amino. The compounds of this invention exhibit therapeutic utility.
REFERENCES:
patent: 2928835 (1960-03-01), Jacob et al.
patent: 3336300 (1967-08-01), Santilli et al.
patent: 3801636 (1974-04-01), Horrom
patent: 5254569 (1993-10-01), Cheeseman et al.
patent: 5364868 (1994-11-01), Englert et al.
patent: 6894054 (2005-05-01), Laborde et al.
patent: 7226917 (2007-06-01), Dargazanli et al.
patent: 7288656 (2007-10-01), Dargazanli et al.
patent: 7300946 (2007-11-01), Ding et al.
patent: 7326722 (2008-02-01), Dargazanli et al.
patent: 7326732 (2008-02-01), Oxford et al.
patent: 7335670 (2008-02-01), Dargazanli et al.
patent: 7507824 (2009-03-01), Gibson et al.
patent: 7619089 (2009-11-01), Dargazanli et al.
patent: 7700585 (2010-04-01), Dargazanli et al.
patent: 2006/0223861 (2006-10-01), Dargazanli et al.
patent: 2006/0223885 (2006-10-01), Dargazanli et al.
patent: 2007/0197601 (2007-08-01), Dargazanli et al.
patent: 2009/0258899 (2009-10-01), Dargazanli et al.
patent: 2010/0022548 (2010-01-01), Dargazanli et al.
patent: 0 365 030 (1990-04-01), None
patent: 0 366 006 (1990-05-01), None
patent: 0499995 (1992-08-01), None
patent: 0 556 672 (1993-08-01), None
patent: WO 92/12128 (1992-07-01), None
patent: WO 99/45011 (1999-10-01), None
patent: WO 03/089411 (2003-10-01), None
patent: WO 2006/110724 (2006-10-01), None
Silverman “Organic chemistry of drug design and drug action” p. 65-73 (1993).
Hashimoto “Glycine transporter inhibitors . . . ” Recent Patents on CNS drug discovery vo.1, p. 43-53 (2006).
Gilfillan et al. “Glycine transporters . . . ” Top Med. chem. v. 4, p. 223-247 (2009).
Lindsley et al. “Design, synthesis . . . ” Chem. Med. Chem. v. 1, p. 807-811 (2006).
Froelich, O., et, al., Asymmetric Synthesis, 39. 1 Synthesis of 2-(1-Aminoalkyl)Piperidines via 2-Cyano-6-Phenyl Oxazolopiperidine, J. Org. Chem. (1996) vol. 61, pp. 6700-6705.
Jonathan H. Lebowitz, A breach in the blood-brain barrier, PNAS (2005, pp. 14485-14486, vol. 102, No. 41).
Mel R., Optical Isomers , Optical Isomers Newton BBS, (2006), Newton.dep.ant.gov.
Richard Daneman et al., The Blood-Brain Barrier—Lessons from Moody Flies, Cell (2005, pp. 9-12, vol. 123, No. 1).
Wilson L. Caulfield at al., The First Potent and Selective Inhibitors of the Glycine Transporter Type 2, Journal of Medicinal Chemistry (2001, pp. 2679-2682, vol. 44, No. 17).
Woods, et. al., Method of Treating Schizophrenia Prodome, CA 145:432223 (2006).
Wermuth et al, Molecular variations based on isoteric replacements, The Practice of Medicinal Chemistry; 1996; pp. 203-207.
Balboni et al, Synthesis and activity of 3-pyridylamine ligands at central nicotinic receptors, Eur. J. Med. Chem., 2000 (35) pp. 979-988.
Beak et al, Alpha-Lithioamine Synthetic Equivalents: Syntheses of Diastereoisomers from Boc Derivatives of Cyclic Amines, J. Org. Chem. 1993, 58, pp. 1109-1117.
Beak et al, Alpha-Lithioamine Synthetic Equivalents: Syntheses of Diastereoisomers from the Boc Piperidines, J. Org. Chem. 1990, 55, pp. 2578-2580.
Braga et al, Making crystals from crystals: a green route to crystal engineering and polymorphism, Chem. Commun., 2005 pp. 3635-3645.
Dutta et al, Potent and Selective Ligands for the Dopamine Transporter (DAT): Structure-Activity Relationship Studies of Novel 4-[2-(Diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine Analogues, J. Med. Chem., 1998 (41) pp. 699-705.
Harsing et al, Glycine Transporter Type-1 and its Inhibitors, Current Medicinal Chemistry, 2006 (13) pp. 1017-1044.
Hodgson et al, III. 3-Nitro-4-amino- and the 3:4-Dihalogenobenzaldehydes, J. Chem. Soc. 1927, pp. 20-27.
Javitt et al, Reversal of Phencyclidine-Induced Effects by Glycine and Glycine Transport Inhibitors, Biol. Psychiatry, 1999 (45) pp. 668-679.
Jeong et al, A New Method for the Preparation of Perfluoroalkylated Triphenylethylene Derivatives, Tetrahedron Letters, 1996 (37) 33, pp. 5905-5908.
Leonetti, M., et. al., 2-Chloro-N-[(S)-Phenyl [(2S)-Piperidin-2-YL] Methyl]-3-Trifluoromethyl Benzamide, Monohydrochloride, an inhibitor of the Glycine Transporter Type 1, Increases Evoked-Dopamine Release in the Rat Nucleus Accumbens In Vivo Via an Enhanced Glutamatergic Neurotransmission, Neuroscience, vol. 137, (2006) pp. 555-564.
Martinelli et al, Aromatic Chlorination of p-Aminobenzoic Acid Derivatives, Improved Syntheses of Mono- and Dichloromethotrexate, J. Org. Chem. 1980 (45) pp. 527-529.
Niemers et al, Pyridylalkyl-substiuierte Amine, Synthesis, Sep. 1976, pp. 593-595.
Ohmomo et al, Synthesis and Evaluation of Iodinated Benzamide Derivatives as Selective and Reversible Monoamine Oxidase B Inhibitors, Chem. Pharm. Bull. 1992 (40) 7, pp. 1789-1792.
Sato et al, A new entry to 9-azabicyclo[3.3.1]nonanes using radical translocation/cyclisation reactions of 2-(but-3-ynyl)-1-(o-iodobenzoyl)piperidines, J. Chem. Soc., Perkin Trans 1, 2002, pp. 1438-1443.
Shimada et al, Synthesis and Gastric Antisecretory Activity of N-cyano-N′-(phenyl-pyridinaylmethyl)guanidine Derivatives, Chem. Pharm. Bull., 1984 (32)12 pp. 4893-4906.
Stewart et al, Synthesis of Substituted 9-Oxo-9,10-dihydroacridine-4-carboxylic Acids. I. Factors Affecting the Direction of Ring Closure of Substituted N-(2-Carboxyphenylamino)benzoic Acids, Aust. J. Chem., 1984 (37) pp. 1939-1950.
Sur, et. al.,, Glycine Transporter I Inhibitors and Modulation of NMDA Receptor-Mediated Excitatory Neurotransmission, Current Drug Targets, 2007 (8) pp. 643-649.
Thai et al, Asymmetric Synthesis and Pharmacology of Methylphenidate and Its Para-Substituted Derivatives, J. Med. Chem., 1998 (41) pp. 591-601.
Dargazanli Gihad
Estenne-Bouhtou Genevieve
Marabout Benoit
Roger Pierre
Sevrin Mireille
Bender Kelly L.
Chang Celia
Sanofi-Aventis
LandOfFree
N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2680155